
CLAIMS:


1. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Phosphate Salt Hydrate Form A, characterized by an X-ray powder diffractogram comprising a signal at 8.6 ± 0.2, 19.9 ± 0.2, and/or 28.3 ± 0.2 two-theta.


2. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** free form Monohydrate, characterized by an X-ray powder diffractogram comprising a signal at 8.7 ± 0.2, 12.8 ± 0.2, 16.7 ± 0.2, and/or 21.7 ± 0.2 two-theta.


3. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Phosphate Salt Methanol Solvate, characterized by an X-ray powder diffractogram comprising a signal at 12.7 ± 0.2, 14.8 ± 0.2, and/or 20.7 ± 0.2 two-theta.


4. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Phosphate Salt MEK Solvate, characterized by an X-ray powder diffractogram comprising a signal at 8.6 ± 0.2, 15.4 ± 0.2, and/or 20.1 ± 0.2 two-theta.


5. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Maleate Salt/Co-Crystal Form A, characterized by an X-ray powder diffractogram comprising a signal at 27.6 ± 0.2 two-theta and 20.0 ± 0.2 two-theta.


6. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Maleate Salt/Co-Crystal Form B, characterized by an X-ray powder diffractogram comprising a signal at 4.9 ± 0.2 two-theta and 26.0 ± 0.2 two-theta.


7. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** Fumaric Acid Salt/Co-Crystal Form A, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 14.4 ± 0.2, 14.6 ± 0.2, 16.9 ± 0.2, 20.7 ± 0.2, 20.9 ± 0.2, and 21.5 ± 0.2.


8. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** free form Form B, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 11.7 ± 0.2, 13.9 ± 0.2, 14.2 ± 0.2, 19.1 ± 0.2, 21.6 ± 0.2, and 24.6 ± 0.2.


9. A solid form of Compound **I**:



(Compound **I**),

wherein the form is Compound **I** free form Form C, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 11.1 ± 0.2, 14.7 ± 0.2, 21.0 ± 0.2, and 25.7 ± 0.2.


10. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** Phosphate Salt Hemihydrate Form A, characterized by an X-ray powder diffractogram comprising a signal at 9.1 ± 0.2, 16.7 ± 0.2, and/or 18.7 ± 0.2 two-theta.


11. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form Hemihydrate Form A, characterized by an X-ray powder diffractogram measured at ambient temperature comprising a signal at 17.1 ± 0.2, 19.1 ± 0.2, and/or 20.4 ± 0.2 two-theta.


12. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form Form C, characterized by an X-ray powder diffractogram measured at ambient temperature comprising a signal at 13.0 ± 0.2 two-theta.


13. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form Form A, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 9.1 ± 0.2, 11.7 ± 0.2, 13.9 ± 0.2, 14.1 ± 0.2, and 20.5 ± 0.2.

14. A solid form of Compound **II**:




(Compound **II**),

wherein the form is Compound **II** free form Form B, characterized by a single crystal unit cell characterized by a monoclinic crystal system, a $P2_1$ space group, and unit cell dimensions measured at 100 K on a Bruker diffractometer equipped Cu Kα radiation (λ=1.54178 Å) of:

a	13.4 ± 0.1 Å	α	90 º
b	8.1 ± 0.1 Å	β	101.1 ± 0.1 º
c	16.0 ± 0.1 Å	γ	90 º.

15. A solid form of Compound **II**:




(Compound **II**),

wherein the form is Compound **II** free form Quarter Hydrate, characterized by a single crystal unit cell characterized by a monoclinic crystal system, a $P2_1$ space group, and unit cell dimensions measured at 100 K on a Bruker diffractometer equipped Cu Kα radiation (λ=1.54178 Å) of:

a	18.9 ± 0.1 Å	α	90 º
b	8.1 ± 0.1 Å	β	99.1 ± 0.1 º
c	22.6 ± 0.1 Å	γ	90 º.


16. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form Hydrate Mixture, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 3.6 ± 0.2, 8.6 ± 0.2, 13.7 ± 0.2, 19.9 ± 0.2, 24.1 ± 0.2, and 24.5 ± 0.2.


17. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form Monohydrate, characterized by a ^{13}C NMR spectrum comprising (a) a signal at 134.1 ± 0.2 ppm and/or a signal at 21.1 ± 0.2 ppm; and (b) one or more signals (*e.g.*, two, three, four, or five) signals chosen from 74.5 ± 0.2 ppm, 62.4 ± 0.2 ppm, 49.0 ± 0.2 ppm, 39.1 ± 0.2 ppm, and 21.7 ± 0.2 ppm.

18. A solid form of Compound **II**:




(Compound **II**),

wherein the form is Compound **II** free form Dihydrate, characterized by a ^{13}C NMR spectrum comprising (a) one or more signals chosen from 143.8 ± 0.2 ppm, 128.9 ± 0.2 ppm,

126.6 ± 0.2 ppm, 68.6 ± 0.2 ppm, 62.7 ± 0.2 ppm, and 37.8 ± 0.2 ppm; and (b) one or more signals chosen from 131.8 ± 0.2 ppm, 124.5 ± 0.2 ppm, 124.1 ± 0.2 ppm, 38.2 ± 0.2 ppm, and 22.5 ± 0.2 ppm.


19. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** EtOH Solvate Form B, characterized by an X-ray powder diffractogram comprising a signal at 11.6 ± 0.2 two-theta, a signal at 17.1 ± 0.2 two-theta, and a signal at 23.8 ± 0.2 two-theta.


20. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form IPA Solvate, characterized by an X-ray powder diffractogram comprising signals at two or more two-theta values chosen from 8.4 ± 0.2, 11.7 ± 0.2, 21.6 ± 0.2, and 23.3 ± 0.2.


21. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form MEK Solvate, characterized by a ^{13}C NMR spectrum comprising a signal at two or more two-theta signals chosen from 8.2 ± 0.2 ppm, 23.2 ± 0.2 ppm, 30.0 ± 0.2 ppm, 35.0 ± 0.2 ppm, 35.7 ± 0.2 ppm 39.3 ± 0.2 ppm, and 63.3 ± 0.2 ppm.


22. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** free form MeOH Solvate, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 13.4 ± 0.2, 16.6 ± 0.2, 24.3 ± 0.2, 24.4 ± 0.2, and 26.3 ± 0.2.


23. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** Phosphate Salt, Acetone Solvate, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 8.7 ± 0.2, 9.4 ± 0.2, 15.0 ± 0.2, and 18.4 ± 0.2.


24. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** Phosphate Salt Form A, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 7.0 ± 0.2, 9.9 ± 0.2, 14.1 ± 0.2, 17.5 ± 0.2 and 19.9 ± 0.2.

25. A solid form of Compound **II**:



(Compound **II**),

wherein the form is Compound **II** Phosphate Salt Form C, characterized by an X-ray powder diffractogram comprising a signal at two or more two-theta values chosen from 13.5 ± 0.2, 13.7 ± 0.2, and 15.0 ± 0.2.








26. A pharmaceutical composition comprising at least one solid form according to any one of claims 1-25 and a pharmaceutically acceptable carrier.

27. Use of at least one solid form according to any one of claims 1-25 in the manufacture of a medicament for the treatment of an APOL1 mediated disease.

28. The use according to claim 27, wherein the APOL1 mediated disease is an APOL1 mediated kidney disease.













29. The use according to claim 28, wherein the APOL1 mediated kidney disease is chosen from ESKD, NDKD, FSGS, HIV-associated nephropathy, arterionephrosclerosis, lupus nephritis, microalbuminuria, and chronic kidney disease.



30. A method of preparing Compound **I** comprising converting a compound selected from:

 **S26/K7**,	 **S3/J6/K8**,	 **L2/K9**,	 **C62/K10,**
 **K11**,	 **S32/K12**, and	 **C153/K13**	








into Compound **I**.

31. A compound selected from:

 **S26/K7**,	 **S3/J6/K8**,	 **L2/K9**,	 **C62/K10,**
 **K11**,	 **S32/K12**,	 **C153/K13**,	 **20a**,
 **L1/K14**,	 **C154/K15**,	 **20b**,	 **K16,**

 **S33/K17**, and	 **C63/K18**.

32. A method of preparing Compound **II** comprising converting a compound selected from:

 **S26/K7**,	 **S2**,	 **L1/K14**,	 **C154/K15**,
 **K16**,	 **S33/K17**, and	 **C63/K18**	

into Compound **II**.

33. At least one solid form according to any one of claims 1-25, for use in therapy.

34. At least one solid form according to any one of claims 1-25 for use in the treatment of an APOL1 mediated disease.

35. The at least one solid form according to claim 34, wherein the APOL1 mediated disease is an APOL1 mediated kidney disease.

36. The at least one solid form according to claim 35, wherein the APOL1 mediated kidney disease is chosen from ESKD, NDKD, FSGS, HIV-associated nephropathy, arterionephrosclerosis, lupus nephritis, microalbuminuria, and chronic kidney disease.